[Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors].
I3I-MIBG has been used for therapy of unresectable neuroendocrine tumors including malignant pheochromocytomas and neuroblastomas in foreign countries since the '80s when its clinical therapeutic trials were initiated. In Japan, 131I-MIBG for therapy has not been approved by Health and Labor Ministry, however, personally imported 131I-MIBG is now available in limited institutions for therapeutic purpose. This guideline draft was made to provide the information about 131I-MIBG radiotherapy including related side effects for doctors, nurses, patients and their families, to prevent the adverse effects of this therapy and to protect radiation injuries from this tracer. The appendices were also attached concerning practical guidance for attending physicians, patient management and referring physicians for their conveniences.
Nakajo
Masayuki
M
Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences.
Yoshinaga
Keiichiro
K
Oriuchi
Noboru
N
Kinuya
Seigo
S
Yokoyama
Kunihiko
K
Yamaguchi
Toshiro
T
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D017410:Practice Guidelines as Topic
D007457:Iodine Radioisotopes; D019797:3-Iodobenzylguanidine